Elenco Poster Discussion Selezionate
ID
N. PGM
Presenting Author
Titolo
26/05/2014
11.45 - 12.45
Antiretroviral Therapy: alternative outcomes
4
PD 1
Substitution of nevirapine or raltegravir for protease inhibitor versus rosuvastatin treatment
for the management of dyslipidemia in HIV-infected patients on stable antiretroviral therapy
(NEVRAST Study). Preliminary results
Leonardo Calza, Bologna
216
PD 2
Changes in routine laboratory tests after switching to co-formulated Rilpivirine-containing
antiretroviral regimen: data from multicenter study group
Massimiliano Fabbiani,
Rome
334
PD 3
T-cell Phenotype and Function following DRV/r-based First cART in HIV+ Patients with Low
CD4 Counts
Camilla Tincati, Milano
40
PD 4
Monotherapy versus Combined Therapy Against Human Immunodeficiency Virus (HIV)-1:
Impact on HIV-1 Reservoir, Immune Activation and Dynamics of Epstein-Barr Virus Coinfection
Maria Raffaella Petrara,
Padova
96
PD 5
Evolution of Cognitive Performance After Simplification to Dual Therapies in HIV+ Patients
Nicoletta Ciccarelli, Rome
259
PD 6
Dynamics of cerebrospinal fluid (CSF) HIV decay and peculiar frequency/spatial features of
EEG-LORETA in ART responder patients with CNS compartmentalized virus
Magdalena Viscione, Rome
332
PD 7
Comparative features of HIV and HCV coinfected migrants vs nationals in the MaSTER cohort
Paola Nasta, Brescia
303
PD 8
Cost assessment of HAART: the Ianua clinical trial in Genoa
Antonio Di Biagio, Genova
26/05/2014
11.45 - 12.45
Comorbidities and coinfections
55
PD 9
Effects of antiretroviral molecules on survival and gene expression of bone markers in an
osteoblast-like cell line
Anna Miserocchi, Bologna
211
PD 10 Bone damage follow-up using calcaneal quantitative ultrasonography (QUS) in HIV-infected
and -uninfected subjects
Raffaella Marocco, Latina
179
PD 11 Prevalence and distribution of abdominal aortic calcification (AAC) and its relationship with
vertebral fractures in HIV positive patients
Nathalie Iannotti, Milano
77
PD 12 Concordance Among Cardiovascular Risk Scores in HIV-positive Patients: Framingham, D:A:
D and Progetto Cuore
Andrea Calcagno, Torino
287
PD 13 Survival after cardiovascular events in HIV-infected patients. Analysis data from a Brescia
cohort
Nigritella Brianese, Brescia
116
PD 14 Human papillomavirus anal infection and anal cytology among HIV-infected and HIVuninfected men who have sex with men
Maria Gabriella Donà,
Rome
149
PD 15 High frequencies of TNF-α-expressing Invariant Natural Killer T (iNKT) cells feature HIV-HBV
co-infected patients
Matteo Basilissi, Milan
182
PD 16 Host innate immune response to HIV and HCV infection: study of dendritic cell compartment
Savinelli Stefano, Rome
27/05/2014
14.15 - 15.15
Antiretroviral therapy: clinical studies and pharmacology
315
PD 17 96-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF – subgroup
analyses by baseline CD4 cells
Antonella Castagna, Milano
288
PD 18 Virological outcomes of first line antiretroviral therapy in routine clinical practice
Manuela Colafigli, Rome
324
PD 19 Dual therapy with Raltegravir associated to different Protease Inhibitors in HIV+ experienced
patients: data of long-term longitudinal follow-up of 192 weeks
Salvatore Martini, Napoli
230
PD 20 Once daily-one pill regimen is correlated to a better adherence 5-years later
Ilaria Mastrorosa, Roma
10
PD 21 Efavirenz dose reduction in HIV-infected patients: a long-term follow-up
Massimiliano Lanzafame,
Verona
Agg.al 09/05/14
Elenco Poster Discussion Selezionate
Presenting Author
ID
N. PGM
245
PD 22 Intracellular Pharmacokinetics of Rilpivirine in HIV-positive Patients Treated with Singletablet Regimen Fixed-dose Combination
Letizia Marinaro, Torino
273
PD 23 Drug concentrations of maraviroc, darunavir and ritonavir as a dual therapy switch in
virologically suppressed patients with R5 virus: results from a multicenter randomized study
(GUSTA)
Roberta Gagliardini, Rome
86
PD 24 Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of
breakthrough during HCV genotype 1 triple therapy.
Chiara Simona Cardellino,
Torino
Titolo
27/05/2014
14.15 - 15.15
Basic and Clinical virology
319
PD 25 Decreasing trends of drug resistance and increase of non-B subtypes amongst subjects
recently diagnosed as HIV infected over the period 2004-2014
Saverio Giuseppe Parisi,
Padova
220
PD 26 Transmitted drug resistance and genetic diversity in Treatment-Naïve HIV-Infected Patients
(2008-2013)
Carmen Rita Santoro, Bari
236
PD 27 Drug resistance transmission clusters in HIV-1 infected patients in central Italy between
1997-2014
Lavinia Fabeni, Roma
295
PD 28 Impact of the HIV-1 subtype associated polymorphism L89M on virological response in
patients starting their first boosted protease-inhibitor containing regimen
Daniele Armenia, Roma
212
PD 29 Analysis of gp41 variability in subjects naïve for antiretrovirals
Marco Franzetti, Milan
99
PD 30 Early clinical response and presence of viral resistant minority variants
Generation GS Junior System
257
PD 31 HIV-1 genotyping in low and very low viral load
Bianca Bruzzone, Genova
188
PD 32 Comparison between pseudoviruses ands T/F IMCs in the synergy of antibody neutralization
Assunta Venuti, Milan
Agg.al 09/05/14
detected by Next
Annapaola Callegaro,
Bergamo